flanders.bio provides you with insights in the vibrant life sciences sector

 

News from flanders.bio and its members

MDxHealth (R) : MDxHealth Notice of Interim Results 2018

MDxHealth SA (Euronext: MDXH.BR) or the "Company" today announced that it will release its interim results for the half year ended 30 June 2018 on Thursday, 30 August 2018.

Finance | 10 August 18
Read more
10
Aug
2018

MDxHealth (R): MDxHealth Shareholder Transparency Declaration

MDxHealth SA (Euronext Brussels: MDXH) ("MDxHealth" or the "Company"), announced that it received on August 3, 2018 the following notification of significant shareholdings in accordance with the Belgian Act of May 2, 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the "Belgian Transparency Act").

10
Aug
2018

argenx to Present at 2018 Wedbush PacGrow Healthcare Conference

argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that the Company will present on Tuesday, August 14th at 1:20 p.m. ET at the 2018 Wedbush PacGrow Healthcare Conference in New York.

10
Aug
2018

Rejuvenate Biomed awarded €460,000 grant from VLAIO to accelerate drug development for healthy aging

CMAST was instrumental in the Grant proposal submission.

 

Rejuvenate Biomed - a biomedical company that researches the biology of aging and applies this knowledge to identify drugs that delay the aging process – today announces it has been awarded a €460K Research Grant by Flanders Innovation & Entrepreneurship (VLAIO). The grant will be used to gain new insights in the aging pathways – which will ultimately contribute to the clinical research and the exploitation of a first lead candidate.

8
Aug
2018

Mithra announces positive top-line results of estelle® phase III oral contraceptive study in eu/russia

Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announced that its Phase III Estelle® study conducted in Europe and Russia successfully met its primary efficacy endpoint. Estelle® is Mithra’s combined oral contraceptive (COC) candidate, composed of Estetrol (E4) 15 mg and drospirenone (DRSP) 3 mg.

10
Aug
2018

MDxHealth (R): MDxHealth Shareholder Transparency Declaration

MDxHealth SA (Euronext Brussels: MDXH) ("MDxHealth" or the "Company"), announced that it received on August 3, 2018 the following notification of significant shareholdings in accordance with the Belgian Act of May 2, 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the "Belgian Transparency Act").

10
Aug
2018

argenx to Present at 2018 Wedbush PacGrow Healthcare Conference

argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that the Company will present on Tuesday, August 14th at 1:20 p.m. ET at the 2018 Wedbush PacGrow Healthcare Conference in New York.

10
Aug
2018

Rejuvenate Biomed awarded €460,000 grant from VLAIO to accelerate drug development for healthy aging

CMAST was instrumental in the Grant proposal submission.

 

Rejuvenate Biomed - a biomedical company that researches the biology of aging and applies this knowledge to identify drugs that delay the aging process – today announces it has been awarded a €460K Research Grant by Flanders Innovation & Entrepreneurship (VLAIO). The grant will be used to gain new insights in the aging pathways – which will ultimately contribute to the clinical research and the exploitation of a first lead candidate.

8
Aug
2018

Mithra announces positive top-line results of estelle® phase III oral contraceptive study in eu/russia

Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announced that its Phase III Estelle® study conducted in Europe and Russia successfully met its primary efficacy endpoint. Estelle® is Mithra’s combined oral contraceptive (COC) candidate, composed of Estetrol (E4) 15 mg and drospirenone (DRSP) 3 mg.

Facts & Figures

CONSULT OUR LIFE SCIENCE DATABASE

 

Innovation is at the core of the life sciences sector and Belgium has a track record of developing ingenious ways to improve the quality of life of millions of people worldwide.

 

Not only extensive life sciences facilities support this high-level technology industry but also financial benefits for R&D companies, international collaborations that guarantee regular cash flow, world known educational systems, a promising product pipeline, and Belgium’s unique central location in Europe.

 

Belgium concentrates on a small territory (30,528 km2) more than 300 life sciences companies with biotech activities. In total, the life sciences sector employs more than 30,000 people (low bound estimation that does not take into account indirect employment generated by the sector). The majority of the companies is related to healthcare, but Belgium also has a strong representation of agricultural and industrial biotech companies.

 

The growing life sciences sector gathers 8 main Belgian universities, 19 research parks and 23 incubators, research institutes, academic hospitals, and clinical research organizations. Biotech companies have access to more than 500,000 square feet of highly flexible infrastructure.

 

Additional assets of Belgium includes: a supportive regulatory and political environment, a highly qualified and productive workforce, a competitive tax environment especially for research companies, a prominent location and an excellent logistical and business infrastructure.

Z Life Sciences

A look behind the scenes of the vibrant life sciences sector in Flanders, Belgium in 11 episodes.

1

VIB

VIB is a life sciences research institute based in Flanders. With more than 1470 scientists from over 60 countries, they perform basic research into the molecular foundations of life and they translate this research into pharmaceutical, agricultural and industrial applications.

2

imec

imec performs world-leading research in nano-electronics and creates groundbreaking innovation in application domains such as healthcare, smart cities and mobility, logistics and manufacturing, and energy. The combination of their widely acclaimed leadership in microchip technology and profound software and ICT expertise is what makes imec unique.

3

Bio Base Europe Pilot Plant

Bio Base Europe Pilot Plant is an independent, state-of-the-art facility that operates from a laboratory level to a multi-ton scale. Bio Base Europe Pilot Plant provides process development, scale-up and custom manufacturing of biobased products and processes. 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?